VIMA Therapeutics

Founded by CEO Bernard Ravina,VIMA Therapeutics is a biotechnology company headquartered in Cambridge, US, specializing in the development of therapies for movement disorders. Established with the aim of addressing unmet medical needs, the company has evolved its strategy to focus on a first-in-class oral medication for dystonia, which is currently in development. VIMA Therapeutics specializes in developing innovative treatments for dystonia and related movement disorders, focusing on a first-in-class oral medication. Their primary product aims to provide symptomatic relief and enhance the quality of life for over 1 million individuals in the U.

S. suffering from dystonia, including more than 100,000 with isolated dystonia. This medication targets specific neurological pathways involved in movement disorders, offering a promising alternative to existing therapies. VIMA Therapeutics plans to distribute its products across the United States, primarily through neurological clinics, hospitals, and specialized healthcare providers, while also educating healthcare professionals and patients on treatment options available for movement disorders.

VIMA Therapeutics generates revenue through direct sales of its flagship oral medicine marketed to healthcare providers and institutions specializing in neurological disorders. The transaction model is characterized as B2B, where healthcare providers purchase the medication directly for patient use, ensuring access to innovative treatment solutions. The company may also establish partnerships with pharmaceutical distributors to expand its reach within the healthcare ecosystem. Revenue is driven by the demand for effective dystonia therapies, with transactions aligned with established pricing plans, reflecting the company’s commitment to making treatments accessible to patients in need.

In March 2026, VIMA Therapeutics raised USD 40 million in series A funding from new investor Frazier Healthcare Partners, with participated from Atlas Venture, Canaan Partners, and Access Industries. The round was part of a larger USD 100 million series A funding.